STRENSIQ is a Subcutaneous Solution in the Human Prescription Drug category. It is labeled and distributed by Alexion Pharmaceuticals, Inc.. The primary component is Asfotase Alfa.
Product ID | 25682-013_09d53de9-6c11-4f9f-9807-9141f9b7a91d |
NDC | 25682-013 |
Product Type | Human Prescription Drug |
Proprietary Name | STRENSIQ |
Generic Name | Asfotase Alfa |
Dosage Form | Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2015-10-23 |
Marketing Category | BLA / BLA |
Application Number | BLA125513 |
Labeler Name | Alexion Pharmaceuticals, Inc. |
Substance Name | ASFOTASE ALFA |
Active Ingredient Strength | 28 mg/.7mL |
Pharm Classes | Alkaline Phosphatase [CS], Tissue-nonspecific Alkaline Phosphatase [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2015-10-23 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA125513 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2015-10-23 |
Marketing Category | BLA |
Application Number | BLA125513 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2015-10-23 |
Ingredient | Strength |
---|---|
ASFOTASE ALFA | 28 mg/.7mL |
SPL SET ID: | 3387574f-5eaa-4501-a71d-4cbfbd563031 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
25682-010 | STRENSIQ | ASFOTASE ALFA |
25682-013 | STRENSIQ | ASFOTASE ALFA |
25682-016 | STRENSIQ | ASFOTASE ALFA |
25682-019 | STRENSIQ | ASFOTASE ALFA |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
STRENSIQ 86105490 4874927 Live/Registered |
Alexion Pharmaceuticals, Inc. 2013-10-30 |